Inclusion Criteria:

          -  Voluntary written informed consent of the patient obtained before any study-specific
             procedure；

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;

          -  Patients with histologically/cytologically confirmed diagnosis of advanced solid
             tumors refractory to standard therapy or for whom no standard therapy exist;

          -  Adequate washing period from last anti-tumor therapy;

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST),
             version 1.1;

          -  The expected survival time for more than 12 weeks;

          -  Adequate bone marrow, hepatic, renal, pancreas, and coagulation function, Blood
             phosphorus and calcium in the normal range.

        Exclusion Criteria:

          -  Prior treatment with selective FGFR inhibitors or multi-target kinase Inhibitors with
             FGFR as the main target;

          -  Unrecovered from any drug-related adverse event to grade ≤ 1 according to the National
             Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.3.0
             derived from any previous anti-tumor treatment, excluding alopecia, Pigmentation, or
             other toxicity with little safety risk for subjects;

          -  Active Central Nervous System (CNS) metastases (brain or leptomeningeal metastases,
             etc.);

          -  Any other history of malignancy within 3 years;

          -  Congenital coagulation abnormalities. Active bleeding or previous history of massive
             bleeding (>30ml within 3 months), history of hemoptysis (more than 5ml fresh bleeding
             within 4 weeks);

          -  Corneal diseases of clinical significance. There is a history of retinal pigment
             epithelial detachment or evidence of the presence of retinal pigment epithelial
             detachment. History of age-related macular degeneration or evidence of age-related
             macular degeneration exists；

          -  Subjects with impaired cardiac function or heart disease of clinical significance;

          -  Pregnant or lactating women.